Aug. 8, 2023 – Problems in the heart and blood vessels such as heart attacks and strokes were reduced 20% among patients taking the popular but expensive weight loss drug Wegovy, according to a trial of more than 17,000 people with overweight or obesity who also had cardiovascular disease.
The company said semaglutide treatment also significantly reduced how often each of these issues occurred. “This is a good result for patients,” said Sattar, who also noted that “we do not know to what extent the weight loss effects of semaglutide, as opposed to its other direct effects on blood vessels or the heart, account for the 20% reduction in cardiovascular events, and more data are needed to try to work this out.”
Several of the early medical options for aiding weight loss had substantial adverse effects, including increased major issues in the heart and blood vessels, a history that led to a lot of caution among doctors over the safety of anti-obesity agents and the wisdom of using medically aided weight loss to produce health benefits.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Source: Reuters - 🏆 2. / 97 Read more »
Novo weight-loss drug Wegovy shows heart benefit in trialNovo Nordisk announced that a trial has revealed that patients taking the weight-loss drug Wegovy had a 20% lower risk of heart attack, stroke, or death from heart disease compared to those on a placebo. This finding gives hope to Novo Nordisk in expanding the perception of Wegovy beyond being just a lifestyle drug.
Source: nypost - 🏆 91. / 67 Read more »
Study: Weight-loss drug Wegovy cuts heart attack risk in those with obesityA recent study has found that the weight-loss drug Wegovy can significantly reduce the risk of heart attacks in individuals with obesity. This discovery could lead to an increased demand for the drug and strengthen the argument for insurance coverage. Experts emphasize that obesity should be treated as a serious illness due to its association with various health issues, including heart disease. However, private insurers have been hesitant to cover Wegovy, and Medicare is currently prohibited from covering weight-loss medications.
Source: washingtonpost - 🏆 95. / 72 Read more »
Popular weight loss drug Wegovy also found to lower the risk of heart attacks, strokesAccording to preliminary results of a new study released by the drug manufacturer, the obesity drug Wegovy reduced the risk of major cardiovascular events by 20% in a clinical trial involving over 17,000 adults aged 45 and older with a history of cardiovascular disease and overweight or obesity.
Source: ABC - 🏆 471. / 51 Read more »